Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study

M. Jafri (Lead / Corresponding author), H. Kristeleit, V. Misra, M. Baxter, S. Ahmed, A. Jegnnathen, A. Jain, D. Maskell, U. Barthakur, G. Edwards, H. Walter, R. Walter, M. A. Khan, A. Borley, P. Nightingale, D. Rea

Research output: Contribution to journalConference article

Abstract

Background: The EMBRACE trial demonstrated significantly improved survival with eribulin compared to physicians’ choice (13.1 vs 10.9 months (p = 0.041). Eribulin has been funded by the NHS in the UK for the management of locally advanced or metastastic breast cancer after at least two lines of treatment. We describe the UK experience of eribulin in this setting.

Methods: Data from 577 patients was analyzed on an individual patient basis from 14 different hospitals after institutional review board approval. Data was collected retrospectively using computerized records and chemotherapy records. Data was collated on: age, breast cancer characteristics, prior chemotherapy regimes, toxicity, PFS and OS. Statistical analysis was performed using SPSS.

Results: Data from 577 patients who received eribulin in specialist cancer centres, teaching hospitals and cancer units throughout the UK between 2011-2017 were included. The median age of patients was 56 (33-84). 447 were ER positive, 129 triple negative, 100 patients were Her2 positive, 1 unknown. The cohort was heavily pre-treated with eribulin being received on average 4thline (median (range 2-11)). The median number of eribulin cycles received were 4 (range 1-29). The OS of the cohort was 288 days (95%CI 260-315), triple negative patients had a worse outcome than ER/Her2 expressing patients (198 c.f. 278 days (p = 0.02)). Less heavily pre-treated patients (≤2 prior treatments) had significantly better survival (328 c.f. 264 days). Patients aged over 65 had better survival 325 c.f. 285 days. 11% experienced grade 3-4 neuropathy, 14% experienced nausea, 19% experienced G3-4 neutropenia, there were no treatment related deaths.

Conclusions: This real world data demonstrates that even in a heavily pretreated population eribulin was associated an OS approaching a year. Eribulin was well tolerated even in patients over 65 and is associated with better survival if used earlier in metastatic patients.
Original languageEnglish
Article number313P
Number of pages1
JournalAnnals of Oncology
Volume29
Issue numberSupplement 8
Early online date23 Oct 2018
DOIs
Publication statusPublished - Oct 2018
EventESMO, Munich 2018 - Munich, Germany
Duration: 18 Oct 201823 Oct 2018
https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar/2018-10-22?q=Baxter+Eribulin&c=abs

Fingerprint

eribulin
Breast Neoplasms
Survival

Keywords

  • breast cancer metastatic
  • eribulin

Cite this

Jafri, M. ; Kristeleit, H. ; Misra, V. ; Baxter, M. ; Ahmed, S. ; Jegnnathen, A. ; Jain, A. ; Maskell, D. ; Barthakur, U. ; Edwards, G. ; Walter, H. ; Walter, R. ; Khan, M. A. ; Borley, A. ; Nightingale, P. ; Rea, D. / Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study. In: Annals of Oncology. 2018 ; Vol. 29, No. Supplement 8.
@article{b8dd4f4f33944bdbb068a6e3f6e53711,
title = "Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study",
abstract = "Background: The EMBRACE trial demonstrated significantly improved survival with eribulin compared to physicians’ choice (13.1 vs 10.9 months (p = 0.041). Eribulin has been funded by the NHS in the UK for the management of locally advanced or metastastic breast cancer after at least two lines of treatment. We describe the UK experience of eribulin in this setting.Methods: Data from 577 patients was analyzed on an individual patient basis from 14 different hospitals after institutional review board approval. Data was collected retrospectively using computerized records and chemotherapy records. Data was collated on: age, breast cancer characteristics, prior chemotherapy regimes, toxicity, PFS and OS. Statistical analysis was performed using SPSS.Results: Data from 577 patients who received eribulin in specialist cancer centres, teaching hospitals and cancer units throughout the UK between 2011-2017 were included. The median age of patients was 56 (33-84). 447 were ER positive, 129 triple negative, 100 patients were Her2 positive, 1 unknown. The cohort was heavily pre-treated with eribulin being received on average 4thline (median (range 2-11)). The median number of eribulin cycles received were 4 (range 1-29). The OS of the cohort was 288 days (95{\%}CI 260-315), triple negative patients had a worse outcome than ER/Her2 expressing patients (198 c.f. 278 days (p = 0.02)). Less heavily pre-treated patients (≤2 prior treatments) had significantly better survival (328 c.f. 264 days). Patients aged over 65 had better survival 325 c.f. 285 days. 11{\%} experienced grade 3-4 neuropathy, 14{\%} experienced nausea, 19{\%} experienced G3-4 neutropenia, there were no treatment related deaths.Conclusions: This real world data demonstrates that even in a heavily pretreated population eribulin was associated an OS approaching a year. Eribulin was well tolerated even in patients over 65 and is associated with better survival if used earlier in metastatic patients.",
keywords = "breast cancer metastatic, eribulin",
author = "M. Jafri and H. Kristeleit and V. Misra and M. Baxter and S. Ahmed and A. Jegnnathen and A. Jain and D. Maskell and U. Barthakur and G. Edwards and H. Walter and R. Walter and Khan, {M. A.} and A. Borley and P. Nightingale and D. Rea",
note = "Presentation 313P",
year = "2018",
month = "10",
doi = "10.1093/annonc/mdy272.303",
language = "English",
volume = "29",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "Supplement 8",

}

Jafri, M, Kristeleit, H, Misra, V, Baxter, M, Ahmed, S, Jegnnathen, A, Jain, A, Maskell, D, Barthakur, U, Edwards, G, Walter, H, Walter, R, Khan, MA, Borley, A, Nightingale, P & Rea, D 2018, 'Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study', Annals of Oncology, vol. 29, no. Supplement 8, 313P. https://doi.org/10.1093/annonc/mdy272.303

Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study. / Jafri, M. (Lead / Corresponding author); Kristeleit, H.; Misra, V.; Baxter, M.; Ahmed, S.; Jegnnathen, A.; Jain, A.; Maskell, D.; Barthakur, U.; Edwards, G.; Walter, H.; Walter, R.; Khan, M. A.; Borley, A.; Nightingale, P.; Rea, D.

In: Annals of Oncology, Vol. 29, No. Supplement 8, 313P, 10.2018.

Research output: Contribution to journalConference article

TY - JOUR

T1 - Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study

AU - Jafri, M.

AU - Kristeleit, H.

AU - Misra, V.

AU - Baxter, M.

AU - Ahmed, S.

AU - Jegnnathen, A.

AU - Jain, A.

AU - Maskell, D.

AU - Barthakur, U.

AU - Edwards, G.

AU - Walter, H.

AU - Walter, R.

AU - Khan, M. A.

AU - Borley, A.

AU - Nightingale, P.

AU - Rea, D.

N1 - Presentation 313P

PY - 2018/10

Y1 - 2018/10

N2 - Background: The EMBRACE trial demonstrated significantly improved survival with eribulin compared to physicians’ choice (13.1 vs 10.9 months (p = 0.041). Eribulin has been funded by the NHS in the UK for the management of locally advanced or metastastic breast cancer after at least two lines of treatment. We describe the UK experience of eribulin in this setting.Methods: Data from 577 patients was analyzed on an individual patient basis from 14 different hospitals after institutional review board approval. Data was collected retrospectively using computerized records and chemotherapy records. Data was collated on: age, breast cancer characteristics, prior chemotherapy regimes, toxicity, PFS and OS. Statistical analysis was performed using SPSS.Results: Data from 577 patients who received eribulin in specialist cancer centres, teaching hospitals and cancer units throughout the UK between 2011-2017 were included. The median age of patients was 56 (33-84). 447 were ER positive, 129 triple negative, 100 patients were Her2 positive, 1 unknown. The cohort was heavily pre-treated with eribulin being received on average 4thline (median (range 2-11)). The median number of eribulin cycles received were 4 (range 1-29). The OS of the cohort was 288 days (95%CI 260-315), triple negative patients had a worse outcome than ER/Her2 expressing patients (198 c.f. 278 days (p = 0.02)). Less heavily pre-treated patients (≤2 prior treatments) had significantly better survival (328 c.f. 264 days). Patients aged over 65 had better survival 325 c.f. 285 days. 11% experienced grade 3-4 neuropathy, 14% experienced nausea, 19% experienced G3-4 neutropenia, there were no treatment related deaths.Conclusions: This real world data demonstrates that even in a heavily pretreated population eribulin was associated an OS approaching a year. Eribulin was well tolerated even in patients over 65 and is associated with better survival if used earlier in metastatic patients.

AB - Background: The EMBRACE trial demonstrated significantly improved survival with eribulin compared to physicians’ choice (13.1 vs 10.9 months (p = 0.041). Eribulin has been funded by the NHS in the UK for the management of locally advanced or metastastic breast cancer after at least two lines of treatment. We describe the UK experience of eribulin in this setting.Methods: Data from 577 patients was analyzed on an individual patient basis from 14 different hospitals after institutional review board approval. Data was collected retrospectively using computerized records and chemotherapy records. Data was collated on: age, breast cancer characteristics, prior chemotherapy regimes, toxicity, PFS and OS. Statistical analysis was performed using SPSS.Results: Data from 577 patients who received eribulin in specialist cancer centres, teaching hospitals and cancer units throughout the UK between 2011-2017 were included. The median age of patients was 56 (33-84). 447 were ER positive, 129 triple negative, 100 patients were Her2 positive, 1 unknown. The cohort was heavily pre-treated with eribulin being received on average 4thline (median (range 2-11)). The median number of eribulin cycles received were 4 (range 1-29). The OS of the cohort was 288 days (95%CI 260-315), triple negative patients had a worse outcome than ER/Her2 expressing patients (198 c.f. 278 days (p = 0.02)). Less heavily pre-treated patients (≤2 prior treatments) had significantly better survival (328 c.f. 264 days). Patients aged over 65 had better survival 325 c.f. 285 days. 11% experienced grade 3-4 neuropathy, 14% experienced nausea, 19% experienced G3-4 neutropenia, there were no treatment related deaths.Conclusions: This real world data demonstrates that even in a heavily pretreated population eribulin was associated an OS approaching a year. Eribulin was well tolerated even in patients over 65 and is associated with better survival if used earlier in metastatic patients.

KW - breast cancer metastatic

KW - eribulin

U2 - 10.1093/annonc/mdy272.303

DO - 10.1093/annonc/mdy272.303

M3 - Conference article

VL - 29

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - Supplement 8

M1 - 313P

ER -